Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Int J Cancer. 2016 Feb 5;138(11):2665–2677. doi: 10.1002/ijc.29992

Figure 2.

Figure 2

KGP94 treatment decreases metastatic tumor burden and improves overall survival. (a) In vivo bone metastasis assay. Representative bioluminescence images of median mice from control and KGP94 treated cohorts. (b) Bone metastases burden in control and KGP94 treated mice measured based on photon flux (photons per second); n≥8. Results are means ± s.e.m, analysis of variance. (c) Kaplan-Meier survival curves of bone metastases bearing mice treated with or without 20 mg/kg KGP94; log-rank test. (d) Representative GFP and H&E images of bone metastases from each experimental group, scale bar= 1 mm. (e) Number of macroscopic metastases in untreated and KGP94 treated mice; n ≥ 8. Line, median; Mann-Whitney test. (f) Distribution of metastases by site.